Myriad Genetics (NASDAQ: MYGN) net income
Myriad Genetics reported a net loss of $365.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $127.3m. Earnings per share were −$3.95.
Myriad Genetics's best year of the last 10 was fiscal 2018. The biggest drop was in fiscal 2019, −96.5%. It reported a loss in 6 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$365.9m | — | −44.4% | −$3.95 |
| 2024 | −$127.3m | — | −15.2% | −$1.41 |
| 2023 | −$263.3m | — | −35.0% | −$3.18 |
| 2022 | −$112.0m | — | −16.5% | −$1.39 |
| 2021 | −$27.2m | — | −3.9% | −$0.35 |
| 2020 | −$223.6m | — | −40.1% | −$2.99 |
| 2019 | $4.6m | −96.5% | 0.5% | $0.06 |
| 2018 | $133.3m | +666.1% | 17.9% | $1.89 |
| 2017 | $17.4m | −85.2% | 2.4% | $0.25 |
| 2016 | $117.2m | — | 15.8% | $1.67 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Myriad Genetics net income compared with its sector
By net income for its latest fiscal year, Myriad Genetics ranks 460th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Myriad Genetics, −44.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 458th | Jazz Pharmaceuticals | −$356.1m | −8.3% |
| 459th | Bausch & Lomb | −$360.0m | −7.1% |
| 460th | Myriad Genetics | −$365.9m | −44.4% |
| 461st | Zenas BioPharma | −$377.7m | −3,777.4% |
| 462nd | Scholar Rock | −$377.9m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Myriad Genetics
- How much did Myriad Genetics earn in fiscal 2025?
- Myriad Genetics reported a net loss of $365.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $127.3m.
- What are the earnings per share of Myriad Genetics?
- They were −$3.95 in fiscal 2025, compared with −$1.41 in fiscal 2024.
- What was the most profitable year for Myriad Genetics?
- Of its last 10 fiscal years, fiscal 2018, with $133.3m.
- Where does Myriad Genetics rank in its sector by net income?
- It ranks 460th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Myriad Genetics come from?
- From the annual report (Form 10-K) that Myriad Genetics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Myriad Genetics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Myriad Genetics: the Myriad Genetics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.